Sermorelin

At a glance

Standard Protocol

GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Pre-Bed Fasted. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.

• Injection site flushing and erythema: the most commonly reported adverse effect; localized redness, warmth, and itching at the injection site within minutes of administration.
• Mild water retention: GH-mediated sodium and fluid retention; the most conservative profile of all GHRH analogs in this database.
• Headache: vasodilation from GH pulse; typically mild and transient.
• Transient facial flushing: immediate post-injection vasodilation.
• Mild lethargy or fatigue: associated with the GH pulse.
• Dizziness: transient; post-injection.
• Nausea: rare at standard doses.
• Mild joint stiffness: GH-related periarticular fluid; less pronounced than CJC-1295 DAC.
• Tingling or numbness: mild paresthesia; less common than with longer-acting GHRH analogs.
• Vivid dreams: GH elevation during nocturnal sleep.
• Mild transient blood sugar changes: less clinically significant than with tesamorelin or HGH 191aa.
• Antibody formation: anti-sermorelin antibodies may develop with extended cycles; may reduce efficacy; clinically significant binding capacity is rare.
• Pituitary downregulation: lower risk than longer-acting GHRH analogs; 4-week washout is adequate for receptor recovery.
• Injection site pain: mild discomfort at subcutaneous administration site.

• Active malignancy: GH stimulation may promote tumor growth.
• History of malignancy: exercise caution; assess risk-benefit before initiating.
• Active acromegaly or conditions involving GH excess.
• Concurrent use with CJC-1295 No DAC, CJC-1295 DAC, or tesamorelin: direct GHRH receptor redundancy; do not stack two GHRH analogs.
• Concurrent use with HGH 191aa: exogenous GH bypasses the pituitary that sermorelin depends on; sermorelin stimulates a pituitary already suppressed by exogenous GH.
• Disruption of the hypothalamic-pituitary axis: pituitary adenoma, cranial radiation, pituitary surgery, or hypopituitarism.
• Concomitant high-dose glucocorticoid therapy: suppresses pituitary GH response.
• Uncontrolled diabetes mellitus or significant insulin resistance: GH elevation worsens glycemic control; monitor fasting glucose.
• Diabetic ketoacidosis.
• Pregnancy: safety not established.
• Breastfeeding: safety not established.
• Known hypersensitivity to sermorelin acetate or any excipients.
• Pediatric use in subjects with closed growth plates.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=Sermorelin